200 related articles for article (PubMed ID: 20961696)
21. Correction of photon attenuation and collimator response for a body-contouring SPECT/CT imaging system.
Seo Y; Wong KH; Sun M; Franc BL; Hawkins RA; Hasegawa BH
J Nucl Med; 2005 May; 46(5):868-77. PubMed ID: 15872362
[TBL] [Abstract][Full Text] [Related]
22. Capromab Pendetide imaging of prostate cancer.
Haseman MK; Rosenthal SA; Polascik TJ
Cancer Biother Radiopharm; 2000 Apr; 15(2):131-40. PubMed ID: 10803318
[TBL] [Abstract][Full Text] [Related]
23. Capromab pendetide scanning has a potential role in optimizing patient selection for salvage cryosurgical ablation of the prostate.
El-Zawahry AM; Clarke HS; Eskridge MR; Rieter W; Onicescu G; Garrett-Mayer E; Gordon LL; Keane TE
Urology; 2010 Nov; 76(5):1162-7. PubMed ID: 20434196
[TBL] [Abstract][Full Text] [Related]
24. Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial.
Schuster DM; Nieh PT; Jani AB; Amzat R; Bowman FD; Halkar RK; Master VA; Nye JA; Odewole OA; Osunkoya AO; Savir-Baruch B; Alaei-Taleghani P; Goodman MM
J Urol; 2014 May; 191(5):1446-53. PubMed ID: 24144687
[TBL] [Abstract][Full Text] [Related]
25. Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life.
Hubosky SG; Fabrizio MD; Schellhammer PF; Barone BB; Tepera CM; Given RW
J Endourol; 2007 Dec; 21(12):1521-31. PubMed ID: 18186694
[TBL] [Abstract][Full Text] [Related]
26. Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy.
Palma D; Tyldesley S; Blood P; Liu M; Morris J; Pickles T;
Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1425-9. PubMed ID: 17394943
[TBL] [Abstract][Full Text] [Related]
27. Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy.
Ding W; Lee J; Chamberlain D; Cunningham J; Yang L; Tay J
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):962-7. PubMed ID: 22494584
[TBL] [Abstract][Full Text] [Related]
28. Indium-111 capromab pendetide in the management of recurrent prostate cancer.
Manyak MJ
Expert Rev Anticancer Ther; 2008 Feb; 8(2):175-81. PubMed ID: 18279057
[TBL] [Abstract][Full Text] [Related]
29. Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma.
Aizer AA; Yu JB; McKeon AM; Decker RH; Colberg JW; Peschel RE
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1344-9. PubMed ID: 19464821
[TBL] [Abstract][Full Text] [Related]
30. Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease?
Zapatero A; García-Vicente F; Martín de Vidales C; Cruz Conde A; Ibáñez Y; Fernández I; Rabadán M
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1279-85. PubMed ID: 20932659
[TBL] [Abstract][Full Text] [Related]
31. Use of 111in-capromab pendetide immunoscintigraphy to image localized prostate cancer foci within the prostate gland.
Mouraviev V; Madden JF; Broadwater G; Mayes JM; Burchette JL; Schneider F; Smith J; Tsivian M; Wong T; Polascik TJ
J Urol; 2009 Sep; 182(3):938-47. PubMed ID: 19616259
[TBL] [Abstract][Full Text] [Related]
32. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.
Gondi V; Deutsch I; Mansukhani M; O'Toole KM; Shah JN; Schiff PB; Katz AE; Benson MC; Goluboff ET; Ennis RD
Urology; 2007 Mar; 69(3):541-6. PubMed ID: 17382161
[TBL] [Abstract][Full Text] [Related]
33. The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy.
Wilkinson S; Chodak G
J Urol; 2004 Jul; 172(1):133-6. PubMed ID: 15201753
[TBL] [Abstract][Full Text] [Related]
34. Procedure for unmasking localization information from ProstaScint scans for prostate radiation therapy treatment planning.
DeWyngaert JK; Noz ME; Ellerin B; Kramer EL; Maguire GQ; Zeleznik MP
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):654-62. PubMed ID: 15380603
[TBL] [Abstract][Full Text] [Related]
35. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
Ko EC; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
[TBL] [Abstract][Full Text] [Related]
36. Detection and localization of carcinoma within the prostate using high resolution transrectal gamma imaging (TRGI) of monoclonal antibody directed at prostate specific membrane antigen (PSMA)--proof of concept and initial imaging results.
Franc BL; Cho SY; Rosenthal SA; Cui Y; Tsui B; Vandewalker KM; Holz AL; Poonamallee U; Pomper MG; James RB
Eur J Radiol; 2013 Nov; 82(11):1877-84. PubMed ID: 23993140
[TBL] [Abstract][Full Text] [Related]
37. Prostate specific antigen only progression of prostate cancer.
Moul JW
J Urol; 2000 Jun; 163(6):1632-42. PubMed ID: 10799151
[TBL] [Abstract][Full Text] [Related]
38. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
39. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
[TBL] [Abstract][Full Text] [Related]
40. Role of ProstaScint for brachytherapy in localized prostate adenocarcinoma.
Ellis RJ; Kim E; Foor R
Expert Rev Mol Diagn; 2004 Jul; 4(4):435-41. PubMed ID: 15225091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
